Yukang Lin Selected Research

Biotin (Vitamin H)

1/2018	CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.
10/2017	Pretargeting with bispecific fusion proteins facilitates delivery of nanoparticles to tumor cells with distinct surface antigens.
11/2016	Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers.
1/2015	Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
2/2014	A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.
12/2011	Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.
11/2010	Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.
7/2010	Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.
9/2007	Pretargeted radioimmunotherapy for B-cell lymphomas.
6/2007	Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yukang Lin Research Topics

Disease

24	Neoplasms (Cancer) 01/2022 - 09/2003
17	Lymphoma (Lymphomas) 10/2017 - 04/2006
8	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2017 - 09/2003
7	B-Cell Lymphoma (Lymphoma, B Cell) 01/2017 - 07/2006
5	Leukemia 12/2020 - 02/2008
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2020 - 04/2006
3	Myeloid Leukemia (Leukemia, Myelocytic) 12/2020 - 01/2009
3	Multiple Myeloma 10/2019 - 02/2014
2	Residual Neoplasm 03/2015 - 11/2010
2	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2015 - 08/2007
2	Hematologic Neoplasms (Hematological Malignancy) 01/2009 - 04/2006
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022
1	Esophageal Squamous Cell Carcinoma 11/2021
1	Anastomotic Leak 11/2021
1	Burkitt Lymphoma (Burkitt's Lymphoma) 01/2015
1	Plasmacytoma 02/2014
1	Mesothelioma 07/2005
1	Ovarian Neoplasms (Ovarian Cancer) 07/2005
1	Neuroblastoma 05/2004
1	Colonic Neoplasms (Colon Cancer) 09/2003

Drug/Important Bio-Agent (IBA)

13	StreptavidinIBA 10/2017 - 07/2005
12	procaine isothiocyanate (PRIT)IBA 12/2020 - 06/2007
11	Proteins (Proteins, Gene)FDA Link 12/2020 - 07/2005
11	Biotin (Vitamin H)FDA Link 01/2018 - 07/2006
8	DOTA-biotin (90Y-DOTA-biotin)IBA 12/2020 - 09/2003
5	Radioisotopes (Radionuclides)IBA 03/2015 - 07/2006
4	Monoclonal AntibodiesIBA 03/2015 - 09/2007
4	Chimeric Antigen ReceptorsIBA 01/2013 - 08/2007
4	AntigensIBA 12/2009 - 06/2007
4	AntibodiesIBA 05/2009 - 07/2006
3	Surface Antigens (Surface Antigen)IBA 10/2017 - 06/2007
3	Indicators and Reagents (Reagents)IBA 01/2015 - 06/2007
3	GalactosamineIBA 07/2010 - 07/2006
3	HLA-DR Antigens (HLA-DR)IBA 05/2009 - 06/2007
3	Immunoconjugates (Immunoconjugate)IBA 09/2007 - 06/2007
2	Astatine-211IBA 10/2019 - 03/2015
2	Glycoproteins (Glycoprotein)IBA 10/2017 - 07/2005
2	LigandsIBA 10/2017 - 09/2003
2	Single-Chain AntibodiesIBA 07/2010 - 07/2005
2	AcetylgalactosamineIBA 05/2009 - 09/2007
2	AcidsIBA 09/2007 - 06/2007
1	Carcinoembryonic AntigenIBA 01/2022
1	Keratin-19 (Keratin 19)IBA 01/2022
1	sintilimabIBA 11/2021
1	venetoclaxIBA 01/2017
1	Cesium-137IBA 01/2017
1	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 01/2015
1	ADP-ribosyl Cyclase 1IBA 02/2014
1	Caspase 9IBA 01/2013
1	BismuthIBA 07/2011
1	Bismuth-213IBA 11/2010
1	Leukocyte Common Antigens (CD45 Antigen)IBA 01/2009
1	Neoplasm Antigens (Tumor Antigens)IBA 06/2007
1	MesothelinIBA 07/2005
1	GD2 gangliosideIBA 05/2004
1	Bovine Serum AlbuminIBA 05/2004
1	Peptides (Polypeptides)IBA 05/2004
1	Gemcitabine FDA Link 09/2003

Therapy/Procedure

18	Radioimmunotherapy 12/2020 - 09/2003
11	Therapeutics 12/2020 - 09/2003
4	Drug Therapy (Chemotherapy) 01/2022 - 09/2007
4	Radiotherapy 01/2017 - 09/2007
2	Immunotherapy 12/2009 - 08/2007
1	Length of Stay 11/2021
1	Injections 12/2020
1	Euthanasia (Mercy Killing) 12/2020
1	Chemoradiotherapy 09/2007
1	Stem Cell Transplantation 09/2007
1	Cell Transplantation 04/2006
1	Combination Drug Therapy (Combination Chemotherapy) 04/2006